A clinical trial reported in the journal Nature-backed release indicates regulatory dendritic cells (DCreg) can enable earlier withdrawal of standard immunosuppressive drugs in living-donor liver transplantation. The approach combines donor-derived regulatory dendritic cells infusion with a protocol to taper conventional immunosuppression sooner. The development addresses a core transplant problem: lifelong immunosuppression exposure and its downstream risks. The trial’s framing emphasizes immune tolerance induction rather than indefinite blockade. If results continue to hold in expanded follow-up, DC-based strategies could become a platform for reducing long-term toxicity in transplant programs while maintaining graft acceptance.